Specific glucocorticosteroid compound having...

Details Specific glucocorticosteroid compound having... Specific glucocorticosteroid compound having...

2007-10-30

2007-10-30

Badio, Barbara P. (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S180000, C552S610000

Reexamination Certificate

active

10564325

ABSTRACT:
A compound of formula (I):whereinX represents O or S;R1represents C1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylmethyl or C3-8cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or R1represents aryl, substituted aryl, heteroaryl or substituted heteroaryl;R2represents hydrogen, methyl, which may be in either the α or β configuration, or methylene;R3and R4are the same or different and each independently represents hydrogen, halogen or a methyl group;andrepresents a single or a double bond;or a physiologically acceptable salt or solvate thereof.

REFERENCES:
patent: 3856828 (1974-12-01), Phillipps et al.
patent: 5552438 (1996-09-01), Christensen, IV
patent: 6172054 (2001-01-01), Clark
patent: 6245804 (2001-06-01), Lehmann et al.
patent: 6395738 (2002-05-01), Ohshima et al.
patent: 6897224 (2005-05-01), Jaroch et al.
patent: 1384372 (1975-02-01), None
patent: 1514476 (1978-06-01), None
patent: 2079755 (1982-01-01), None
patent: 2137206 (1984-10-01), None
patent: WO89/03390 (1989-04-01), None
patent: WO93/13055 (1993-07-01), None
patent: WO95/34534 (1995-12-01), None
patent: WO97/41867 (1997-11-01), None
patent: WO98/30537 (1998-07-01), None
patent: WO98/54159 (1998-12-01), None
patent: WO99/16766 (1999-04-01), None
patent: WO99/32127 (1999-07-01), None
patent: WO99/47505 (1999-09-01), None
patent: WO99/62875 (1999-12-01), None
patent: WO 00/66590 (2000-11-01), None
patent: WO 01/04118 (2001-01-01), None
patent: WO 01/10143 (2001-02-01), None
patent: WO 01/16128 (2001-03-01), None
patent: WO 01/42193 (2001-06-01), None
patent: WO 02/00679 (2002-01-01), None
patent: WO 02/02565 (2002-01-01), None
patent: WO 02/26722 (2002-04-01), None
patent: WO 02/40030 (2002-05-01), None
patent: WO 02/50021 (2002-06-01), None
patent: WO 02/66422 (2002-08-01), None
patent: WO 02/70490 (2002-09-01), None
patent: WO 02/76933 (2002-10-01), None
patent: WO 03/08277 (2003-01-01), None
patent: WO 03/024439 (2003-03-01), None
patent: WO 03/042160 (2003-05-01), None
patent: WO 03/059899 (2003-07-01), None
patent: WO 03/061651 (2003-07-01), None
patent: WO 03/072539 (2003-09-01), None
patent: WO 03/082280 (2003-10-01), None
patent: WO 03/082787 (2003-10-01), None
patent: WO 03/082827 (2003-10-01), None
patent: WO 03/086294 (2003-10-01), None
patent: WO 03/091204 (2003-11-01), None
patent: WO 03/101932 (2003-12-01), None
patent: WO 03/104195 (2003-12-01), None
patent: WO 04/005229 (2004-01-01), None
patent: WO 04/009016 (2004-01-01), None
patent: WO 04/009017 (2004-01-01), None
patent: WO 04/016578 (2004-02-01), None
patent: WO 04/018429 (2004-03-01), None
patent: WO 04/022547 (2004-03-01), None
patent: WO 04/024728 (2004-03-01), None
patent: WO 04/026248 (2004-04-01), None
patent: WO 04/037768 (2004-05-01), None
patent: WO 04/037773 (2004-05-01), None
patent: WO 04/037807 (2004-05-01), None
patent: WO 04/039762 (2004-05-01), None
patent: WO 04/039766 (2004-05-01), None
patent: WO 04/056823 (2004-07-01), None
patent: WO 04/103998 (2004-12-01), None
Ueno et al., “Synthesis and evaluation of anti-inflammatory activities of a series of corticosteroid 17.alpha.-esters containing a functional group,”Journal of Medicinal Chemistry34(8):2468-2473 (Aug. 1991).
Austin et al., “Mometasone Furoate is a less specific glucocorticoid than fluticasone propionate,”Eur Resp J.20(6):1386-1392 (Dec. 2002).
Fuji et al., “Novel phosphodiesterase 4 inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen,”J Pharmacol Exp Ther284(1):162 (1998).
Landells et al., “Oral administration of the phosphodiesterase (PDE)4 inhibitor, V11294A inhibits ex-vivo agonist-induced-cell activation,”Eur Resp J(/annu Cong Eur Resp Soc, Geneva) 12(suppl. 28) Abst P2393 (Sep. 1998).
Phillipps et al., Synthesis and Structure-Activity relationships in a series of anti-inflammatory corticosteroid analogues, halomethyl androstane-17β-carbothioates and—17β-carboselenoates,πJ. Med. Chem. 37(22):3717-3729 (1994).
Rachwal et al., “Chemistry of loteprednol etabonate and related steroids. II. Reactions at ring C and NMR structural studies of the resulting compounds.”Steroids63 (4): 193-201 (1998).
Ray et al., “Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor χ and inhibition by glucocorticoids,”Biochem J. 328:707-715 (Dec. 1997).

Affiliated with

Also associated with

Rating

Specific glucocorticosteroid compound having... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Specific glucocorticosteroid compound having..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Specific glucocorticosteroid compound having... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3877250